公开(公告)号：US10905664B2

公开(公告)日：2021-02-02

申请号：US16827622

申请日：2020-03-23

申请人： DR. REDDY'S LABORATORIES LTD.

发明人： Swati Kulkarni ,  Bijay Kumar Padhi ,  Shanvas Alikunju ,  Rajeev Singh Raghuvanshi ,  Srinivas Ramchandra Sidgiddi ,  Anirudh Gautam

IPC分类号： A61K31/165 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61K31/65 ,  A61P17/04 ,  A61P17/00 ,  A61P29/00 ,  A61K9/00

摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

公开(公告)号：US11191740B2

公开(公告)日：2021-12-07

申请号：US16241754

申请日：2019-01-07

申请人： DR. REDDY'S LABORATORIES LTD.

发明人： Swati Kulkarni ,  Bijay Kumar Padhi ,  Shanvas Alikunju ,  Rajeev Singh Raghuvanshi ,  Srinivas Ramchandra Sidgiddi ,  Anirudh Gautam

IPC分类号： A61K31/165 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61K31/65 ,  A61P17/04 ,  A61P17/00 ,  A61P29/00 ,  A61K9/00

摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.

公开(公告)号：US11364212B2

公开(公告)日：2022-06-21

申请号：US17132825

申请日：2020-12-23

申请人： DR. REDDY'S LABORATORIES LTD.

发明人： Swati Kulkarni ,  Bijay Kumar Padhi ,  Shanvas Alikunju ,  Rajeev Singh Raghuvanshi ,  Srinivas Ramchandra Sidgiddi ,  Anirudh Gautam

IPC分类号： A61K31/165 ,  A61P17/02 ,  A61P17/06 ,  A61P17/10 ,  A61K31/65 ,  A61P17/04 ,  A61P17/00 ,  A61P29/00 ,  A61K9/00

摘要： The present application relates to a method of treating an inflammatory skin condition by administering a pharmaceutical composition comprising a reduced dose of minocycline to a subject in need thereof, wherein said administration provides an effective plasma or interstitial fluid concentration of minocycline for treating the inflammatory skin condition.